Re: Ito et al. Prognostic impact of C-reactive protein for determining overall survival of patients with castration-resistant prostate cancer treated with docetaxel (Urology 2011;78:1131-1135). [electronic resource]
- Urology Jun 2012
- 1414; author reply 1414-5 p. digital
Publication Type: Letter; Comment
1527-9995
10.1016/j.urology.2011.12.051 doi
Antineoplastic Agents--therapeutic use C-Reactive Protein--analysis Humans Male Orchiectomy Prostatic Neoplasms--blood Taxoids--therapeutic use